Changes in Bone Density, Radiographic Texture Analysis and Bone Turnover During Two Years of Antiresorptive Therapy for Postmenopausal Osteoporosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Changes in Lumbar Spine BMD +/- Treatment With Alendronate
研究概览
简要总结
The purpose of this study is to determine if a new test for osteoporosis can be useful in monitoring treatment. We are studying a new method for examining the quality of bone by an experimental method of computerized analysis of radiographic images (x-ray pictures) of the heel.
详细描述
The study proposed in this application is a part of a larger project entitled "Clinical utility of radiographic texture analysis in diagnosing and treating osteoporosis". The overall goal of the larger project is to determine whether computerized texture analysis of digitized high-resolution images of trabecular bone (texture analysis) improves our ability to diagnose bone fragility and follow natural history and/or response to pharmacological therapy of osteoporosis. In the study proposed here we plan to examine changes in the results of texture analysis during two years of pharmacological therapy for osteoporosis.
Role of densitometry in osteoporosis:
Measurement of bone mineral density is the principal diagnostic method used in clinical practice and in research studies, both to identify patients who have the disease and to follow their response to therapeutic agents. The technique used most widely is dual-energy X-ray absorptiometry (DXA), which has advantages of low cost and radiation exposure, and high precision and accuracy of 1-2% and 4-8%, respectively [Garner, 1996 and Melton, 1990]. Based on the association between the low BMD and increased risk of fracture, BMD-based treatment guidelines have been developed [Melton, 1993 and National Osteoporosis Foundation, 1999]. There is, however, a considerable overlap between BMD of patients who sustain fragility fractures and those who do not [Cummings, 1993; Marshall, 1996; Melton, 1989; Ross, 1990 and Wasnich, 1990]. The problem arises because the fragility is determined not only by the quantity of the bone (measured as bone density), but also by its "quality" which is believed to be related to the preservation of the normal trabecular pattern [Parfitt, 1987]. Bone quality is not specifically assessed using current diagnostic methods. Information about bone quality, however, would be of substantial clinical and scientific value, as it would complement the BMD measurement when selecting patients for therapy and when studying bone loss or assessing effects of therapeutic agents.
Texture analysis:
A novel approach to noninvasive and practical assessment of bone structure is to analyze the texture of high resolution radiographs of trabecular bone [Link, 1999]. Dr. Giger has developed a method for characterizing bone structure by computerized texture analysis of digitized high-resolution radiographs [Jiang, 1999; Caligiuri, 1993; Caligiuri, 1994; Chinander, 1999 and Chinander, 2000]. In this approach, the texture is analyzed in several ways, including Fourier based analysis, which yields root mean square (RMS) as a measure of magnitude of trabecular bone texture pattern, and the first moment of power spectrum (FMP) which characterizes the texture pattern's frequency; and Minkowski dimension fractal analysis [Caligiuri, 1993; Chinander, 1999; Chinander, 2000; Benhamou, 1994; Jiang, 1999; Majumdar, 1993 and Maragos, 1994]. Radiographic texture analysis has been studied in vivo, on lumbar spine radiographs and found to predict presence of vertebral fractures elsewhere in the spine more reliably than did the BMD of the spine [Caligiuri, 1993 and Caligiuri, 1994;]. In addition, in an in vitro study texture features as well as BMD were analyzed in femoral neck specimens obtained during surgical hip replacement. Mechanical loading (crush test) was then performed on cubes of trabecular bone machined from these specimens to determine their bone strength. It was found that the combination of BMD and texture analysis predicted bone strength better than BMD alone [Jiang, 1999; Chinander, 1999 and Chinander, 2000].
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 59 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The study will enroll 40 postmenopausal women with a T score < -2 either at the lumbar spine or the femoral neck: 20 who decide to begin anti-resorptive therapy (treated group), and 20 women who decline such therapy (control group). We will attempt to match the patients and the controls for T score (within 0.3) and age (within 5 years).
- •All study participants will be:
- •at least 3 years past the last menstrual period,
- •not on HRT, Raloxifene or calcitonin for at least 6 months.
排除标准
- •All study participants will not be on bisphosphonates during the previous 12 months.
- •Women with secondary causes of osteoporosis will be excluded.
研究组 & 干预措施
Experimental
All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
干预措施: Alendronate (Drug)
Experimental
All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
干预措施: Calcium Citrate (Dietary Supplement)
Experimental
All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
干预措施: Vitamin D (Dietary Supplement)
Control
All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
干预措施: Calcium Citrate (Dietary Supplement)
Control
All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
干预措施: Vitamin D (Dietary Supplement)
结局指标
主要结局
Changes in Lumbar Spine BMD +/- Treatment With Alendronate
时间窗: Baseline to Month 24
Percent Change in lumbar spine BMD from Baseline to Month 24
次要结局
- Changes in Peripheral Heel BMD +/- Treatment With Alendronate(Baseline to Month 24)
- Changes in Femoral Neck BMD +/- Treatment With Alendronate(Baseline to Month 24)
- Changes in Total Hip BMD +/- Treatment With Alendronate(Baseline to Month 24)
- Changes in Radiographic Texture Analysis (RTA) Integrated Root Mean Square (iRMS) From Baseline to Month 24(Baseline to Month 24)
- Changes in Radiographic Texture Analysis (RTA) Feature Standard Deviation of Root Mean Square (sdRMS) From Baseline to Month 24(Baseline to Month 24)
- Changes in Radiographic Texture Analysis (RTA) Feature Integrated First Moment of the Power Spectrum (iFMP) From Baseline to Month 24(Baseline to Month 24)
- Changes in Radiographic Texture Analysis (RTA) Minimum First Moment of the Power Spectrum (minFMP) From Baseline to Month 24(Baseline to Month 24)
- Changes in Radiographic Texture Analysis (RTA) Minkowski Fractal Dimension (MINK) From Baseline to Month 24(Baseline to Month 24)
- Changes in Radiographic Texture Analysis (RTA) Spectral Density Coefficient Beta (BETA) From Baseline to Month 24(Baseline to Month 24)
